This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhou, Y. Articles by Klibanski, A. Search for Related Content PubMed PubMed Citation Articles by Zhou, Y. Articles by Klibanski, A.

Truncated Activin Type I Receptor Alk4 Isoforms Are Dominant Negative Receptors Inhibiting Activin Signaling

Neuroendocrine Unit Massachusetts General Hospital and Harvard Medical School Boston, Massachusetts 02114

Activin, a member of the transforming growth factor ß (TGFß) superfamily of cytokines, inhibits cell proliferation in a variety of cell types. The functions of activin are mediated by type I and type II serine/threonine kinase receptors. The main type I receptor mediating activin signaling in human cells is ActRIB, also called Alk4. We have previously reported that several truncated Alk4 receptor isoforms are exclusively expressed in human pituitary tumors, and that the majority of such tumors did not exhibit activin-induced growth arrest in culture. We therefore studied the function of these truncated receptor isoforms. Transient expression of these truncated receptors inhibited activin-activated transcription from an activin-responsive reporter construct, 3TPLux. When each of these truncated Alk4 receptors was stably transfected into K562 cells, activin-induced expression of an endogenous gene, junB, was blocked, indicating that inhibition of gene expression also occurred at the chromosomal level. Furthermore, activin administration failed to cause growth inhibition and an increase of the G₁ population in these cells. Coimmunoprecipitation experiments showed that the truncated Alk4 receptors formed complexes with type II activin receptors, but were not phosphorylated. These data indicate that the truncated activin type I receptors, predominantly expressed in human pituitary adenomas, function as dominant negative receptors to interfere with wild-type receptor function and block the antiproliferative effect of activin. This may contribute to uncontrolled pituitary cell growth and the development of human pituitary tumors.

This article has been cited by other articles:

				M. R. Muller, F. Zheng, S. Werner, and C. Alzheimer Transgenic Mice Expressing Dominant-negative Activin Receptor IB in Forebrain Neurons Reveal Novel Functions of Activin at Glutamatergic Synapses J. Biol. Chem., September 29, 2006; 281(39): 29076 - 29084. [Abstract] [Full Text] [PDF]

				J. E. Burdette, J. S. Jeruss, S. J. Kurley, E. J. Lee, and T. K. Woodruff Activin A Mediates Growth Inhibition and Cell Cycle Arrest through Smads in Human Breast Cancer Cells Cancer Res., September 1, 2005; 65(17): 7968 - 7975. [Abstract] [Full Text] [PDF]

				C. Bamberger, A. Scharer, M. Antsiferova, B. Tychsen, S. Pankow, M. Muller, T. Rulicke, R. Paus, and S. Werner Activin Controls Skin Morphogenesis and Wound Repair Predominantly via Stromal Cells and in a Concentration-Dependent Manner via Keratinocytes Am. J. Pathol., September 1, 2005; 167(3): 733 - 747. [Abstract] [Full Text] [PDF]

				P L Hanson, S J B Aylwin, J P Monson, and J M Burrin FSH secretion predominates in vivo and in vitro in patients with non-functioning pituitary adenomas Eur. J. Endocrinol., March 1, 2005; 152(3): 363 - 370. [Abstract] [Full Text] [PDF]

				Y. Zhou, S. Scolavino, S. F. Funderburk, L. F. Ficociello, X. Zhang, and A. Klibanski Receptor Internalization-Independent Activation of Smad2 in Activin Signaling Mol. Endocrinol., July 1, 2004; 18(7): 1818 - 1826. [Abstract] [Full Text] [PDF]

				A. Lacerte, E.-H. Lee, R. Reynaud, L. Canaff, C. de Guise, D. Devost, S. Ali, G. N. Hendy, and J.-J. Lebrun Activin Inhibits Pituitary Prolactin Expression and Cell Growth through Smads, Pit-1 and Menin Mol. Endocrinol., June 1, 2004; 18(6): 1558 - 1569. [Abstract] [Full Text] [PDF]

				C. A. Harrison, P. C. Gray, S. C. Koerber, W. Fischer, and W. Vale Identification of a Functional Binding Site for Activin on the Type I Receptor ALK4 J. Biol. Chem., May 30, 2003; 278(23): 21129 - 21135. [Abstract] [Full Text] [PDF]

				Y. Zhou, K. R. Mehta, A. P. Choi, S. Scolavino, and X. Zhang DNA Damage-induced Inhibition of Securin Expression Is Mediated by p53 J. Biol. Chem., January 3, 2003; 278(1): 462 - 470. [Abstract] [Full Text] [PDF]

				D. C. Danila, X. Zhang, Y. Zhou, J. N. S. Haidar, and A. Klibanski Overexpression of Wild-Type Activin Receptor Alk4-1 Restores Activin Antiproliferative Effects in Human Pituitary Tumor Cells J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4741 - 4746. [Abstract] [Full Text] [PDF]

				C. Bianco, H. B. Adkins, C. Wechselberger, M. Seno, N. Normanno, A. De Luca, Y. Sun, N. Khan, N. Kenney, A. Ebert, et al. Cripto-1 Activates Nodal- and ALK4-Dependent and -Independent Signaling Pathways in Mammary Epithelial Cells Mol. Cell. Biol., April 15, 2002; 22(8): 2586 - 2597. [Abstract] [Full Text] [PDF]

				Y.-G. Chen, H. M. Lui, S.-L. Lin, J. M. Lee, and S.-Y. Ying Regulation of Cell Proliferation, Apoptosis, and Carcinogenesis by Activin Experimental Biology and Medicine, February 1, 2002; 227(2): 75 - 87. [Abstract] [Full Text] [PDF]